FDA Unveils Groundbreaking AI-Driven Real-Time Clinical Trial Oversight with AstraZeneca and Amgen as First Participants

ThisReal-time Clinical Trial (RTCT) Plan to Pass ThroughArtificial Intelligence and Data Science Technology，LetFDA views safety signals and clinical endpoints in the cloud in real time.Point, without the needAwaiting data collection, analysis, and submission.

FDA stated that it has currently approved AI healthcare companies.Paradigm HealthThe platform received and verifiedThe signal in AstraZeneca's trial confirmed the feasibility of the technical framework required for real-time signal sharing.

Paradigm Health, founded in 2019, is dedicated to revolutionizing the clinical research ecosystem through an AI-driven platform.AlreadyForGlobally Top20BigMedicineIn China15Provided by Paradigm Health, Inc.

Notably, Paul Kluetz, Chief Medical Officer of Paradigm Health, previously served as the Deputy Director of the FDA's Oncology Center of Excellence. He joined the company almost immediately after leaving the FDA in March.

The FDA once launchedGenerative AI Tools

As early as 2025, the FDA began to introduce AI technology toAccelerate the drug development process.

In December last year, the FDA launchedGenerateParadigm HealthArtificial Intelligence Tool Elsa, can be used to performSuch as meeting management, pre-market review, post-market surveillance and inspections, andClaimed that 70% of employees voluntarily used Elsa.

This model is built in the highly secure GovCloud environment, not trained on input data or data submitted by regulated industries, protecting the sensitive research and data handled by FDA staff.

For this time'sReal-Time Clinical Trials (RTCT) Program Inspires Confidence Within the FDA.Chief Artificial Intelligence Officer Jeremy WalshIndicates:

"Real-time adjudication has been discussed for many years. We have demonstrated that it is not only feasible but also has transformative potential for the clinical trial ecosystem."

—The End—

Recommended Reading